Abridge vs Manus AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.
About
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.
General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.
About
Manus AI is a general-purpose autonomous AI agent developed by Butterfly Effect Pte Ltd, founded in 2022 by Yichao "Peak" Ji and Xiao Hong. Relocated from China to Singapore (mid-2025). Launched March 6, 2025, autonomously handling complex tasks like market research, coding, data analysis, and content creation without human intervention.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.